Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007;3(1):23-30.

Moexipril and left ventricular hypertrophy

George S Chrysant  1 , P K Nguyen
Affiliations
Review

Moexipril and left ventricular hypertrophy

George S Chrysant et al. Vasc Health Risk Manag. 2007.

Abstract

Angiotensin-converting enzyme (ACE) inhibitors today are the standard therapy of patients with myocardial infarction and heart failure due to their proven beneficial effects in left ventricular remodeling and left ventricular function. ACE inhibitors have also been demonstrated to lead to regression of left ventricular hypertrophy (LVH). It is believed that the mechanism of action of LVH regression with ACE inhibitors arises from more than simple blood pressure reduction. LVH is an important risk factor for cardiovascular disease morbidity and mortality independent of blood pressure. Moexipril hydrochloride is a long-acting, non-sulfhydryl ACE inhibitor that can be taken once daily for the treatment of hypertension. Moexipril has now also been demonstrated to have beneficial effects on LVH and can lead to LVH regression.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Classical and alternative pathways of angiotensin II production.
Figure 2
Figure 2
Tissue level stimulation and inhibition of angiotensin II.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Abernethy DR, Fox AAL, Stimpel M. Moexipril in the treatment of mild to moderate essential hypertension: comparison with sustained release varapamil. J Clin Pharmacol. 1995;35:795–9. - PubMed
    1. Agabiti-Rosei E, Ambrosioni E, Pirelli, et al. Efficacy and tolerability of moexipril and nitrendipine in postmenopausal women with hypertension: MADAM study group. Eur J Clin Pharmacol. 1999;55:185–9. - PubMed
    1. Barfour JA, Gos KL. Benazepril, a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in hypertension and congestive heart failure. Drugs. 1995;42:511–39. - PubMed
    1. Brilla CG, Maubara I, Weber KT. Advanced hypertensive heart disease in spontaneously hypertensive rats: lisinopril-medicated regression of myocardial fibrosis. Hypertension. 1996;28:269–74. - PubMed
    1. Chrysant SG. Antihypertensive effectiveness of low dose lisinoprilhydrochlorothiazide combinations: a large multicenter study. Arch Intern Med. 1994;154:737–43. - PubMed

MeSH terms

Substances